Outpatient Management of Alcohol Withdrawal
Outpatient alcohol withdrawal management is appropriate for patients with mild to moderate withdrawal symptoms who lack high-risk features, using oral benzodiazepines with daily monitoring and mandatory thiamine supplementation. 1
Patient Selection for Outpatient Management
Exclude patients with the following high-risk features from outpatient treatment:
- History of withdrawal seizures or delirium tremens 1
- Significant/severe alcohol withdrawal syndrome 1
- High levels of recent drinking 1
- Co-occurring serious medical illness (liver failure, respiratory failure, recent head trauma, advanced age, obesity) 1
- Co-occurring serious psychiatric illness 1
- Previous failure of outpatient treatment 1
- Lack of stable/safe living environment or adequate social support 2
Outpatient treatment is cost-effective with equivalent 6-month abstinence rates compared to inpatient care when patients are appropriately selected 1.
Medication Regimen
Benzodiazepines (First-Line Treatment)
Long-acting benzodiazepines are preferred for outpatient management:
- Chlordiazepoxide: 25-100 mg orally every 4-6 hours, tapered over time 1
- Diazepam: 5-10 mg orally every 6-8 hours, tapered over time 1
These provide superior seizure prevention through GABA activation 1. The 2018 EASL guidelines recommend symptom-triggered regimens rather than fixed-dose schedules to prevent drug accumulation 1.
For patients with hepatic dysfunction, advanced age, or respiratory compromise, use intermediate-acting benzodiazepines:
- Lorazepam: 1-4 mg orally every 4-8 hours, starting at 6-12 mg/day total, tapered following symptom resolution 1
Benzodiazepines should not be used beyond 10-14 days due to abuse potential 1.
Alternative Agents
Carbamazepine 200 mg orally every 6-8 hours can be used as an alternative for seizure prevention, though it does not prevent seizures as effectively as benzodiazepines 1, 3.
Mandatory Thiamine Supplementation
All patients must receive thiamine 100-300 mg/day orally for prevention of Wernicke encephalopathy, continued for 2-3 months (or 4-12 weeks minimum) after withdrawal symptom resolution 1. Thiamine must be administered before any glucose-containing IV fluids to prevent precipitating acute thiamine deficiency 1.
Monitoring Protocol
Symptom Assessment
Use the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale for monitoring, though recognize it has limitations and should not be used for diagnosis alone 1. A CIWA-Ar score >8 indicates moderate AWS requiring pharmacological treatment, and ≥15 indicates severe AWS 1.
Daily physician visits are required until symptoms subside 3. Monitor for:
- Vital signs (blood pressure, pulse rate) 1
- Tremors, hyperreflexia 1
- Agitation, anxiety, irritability 1
- Nausea, vomiting 1
- Hallucinations 1
- Signs of progression to severe withdrawal 1
Laboratory Monitoring
Evaluate electrolytes (especially magnesium), hepatic function, and screen for infections and substance use 1.
Supportive Care
Provide:
- Adequate hydration and fluid management 1
- Electrolyte replacement (especially magnesium) 1
- Comfortable, low-stimulation environment 1
- Multivitamin supplementation 1
Psychiatric Consultation and Long-Term Planning
Psychiatric consultation is strongly recommended (A1 recommendation) for evaluation, acute management, and long-term abstinence planning 1. This addresses the reality that effective acute withdrawal treatment is only an initial step; long-term success depends on facilitating entry into ongoing treatment 3.
Critical Pitfalls to Avoid
- Never use CIWA scores alone for diagnosis - high scores can occur with anxiety disorders, anxiolytic withdrawal, sepsis, hepatic encephalopathy, or severe pain 1
- Never give glucose before thiamine - this can precipitate Wernicke encephalopathy 1
- Never use haloperidol as monotherapy - only use carefully as adjunctive therapy for agitation or hallucinations not controlled by benzodiazepines 1
- Never continue benzodiazepines beyond 10-14 days due to abuse risk 1
- Never discharge without arranging follow-up - daily monitoring is essential until symptom resolution 3